HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Platelet Aggregation Inhibitors (Antiplatelet Drugs)

Subscribe to New Research on Platelet Aggregation Inhibitors

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.

Also Known As:

Antiplatelet Drugs; Blood Platelet Aggregation Inhibitors; Blood Platelet Antagonists; Blood Platelet Antiaggregants; Platelet Inhibitors; Agents, Antiplatelet; Aggregation Inhibitors, Platelet; Antagonists, Blood Platelet; Antagonists, Platelet; Antiaggregants, Blood Platelet; Drugs, Antiplatelet; Inhibitors, Platelet; Inhibitors, Platelet Aggregation; Antiaggregants, Platelet; Antiplatelet Agents; Platelet Antagonists; Platelet Antiaggregants

Networked: 2507 relevant articles (205 outcomes, 286 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 56
  - Therapeutic Uses: 297
    - Hematologic Agents: 1
      - Platelet Aggregation Inhibitors: 2507

Experts

1.	Lip, Gregory Y H: 18 articles (06/2015 - 12/2003)
2.	Diener, Hans-Christoph: 11 articles (10/2015 - 08/2004)
3.	Bhatt, Deepak L: 11 articles (10/2013 - 08/2004)
4.	Serebruany, Victor L: 10 articles (01/2016 - 01/2004)
5.	Aronow, Wilbert S: 9 articles (08/2013 - 11/2003)
6.	Angiolillo, Dominick J: 8 articles (10/2015 - 04/2007)
7.	Alberts, Mark J: 8 articles (12/2011 - 01/2002)
8.	Algra, Ale: 7 articles (10/2015 - 09/2003)
9.	Uchiyama, Shinichiro: 7 articles (02/2015 - 01/2009)
10.	Huber, Kurt: 7 articles (11/2014 - 03/2008)

Related Diseases

1.	Stroke (Strokes) 01/01/2013 - "Anticoagulant and/or antiplatelet agents are usually recommended for stroke prevention;however, such treatments remain highly controversial, and there are inadequate data to compare the efficacy of anticoagulation and antiplatelet therapy. " 10/01/2012 - "Those who improved had significantly lower systolic blood pressure before thrombolysis and were less often administered antiplatelet agents before index stroke. " 09/01/2009 - "In the cases of distal embolic stroke, all three patients achieved good results following the use of antiplatelet agents. " 10/01/2003 - "Although antiplatelet agents have not proved to be beneficial in the primary prevention of stroke, they are recommended in patients with ICS in order to lower the risk of heart attack associated with this pathology. " 01/01/2010 - "Prior major clinical trials of various secondary stroke prevention regimens pointed to a greater efficacy of dual antiplatelet agents if initiated early from symptom onset. "
2.	Thrombosis (Thrombus) 07/01/2014 - "The former is characterized by thrombus formation under fast blood flow, platelet activation, thrombus consisting most platelet and effectively treated by antiplatelet agents. " 07/01/2012 - "There is considerable inter-individual variation in the efficacy of established antiplatelet drugs, and high on-treatment platelet reactivity is associated with an increased risk of cardiovascular events, thus prompting the search for novel drugs against platelet-dependent thrombosis. " 01/01/1989 - "Data from meta-analysis and from more recent trials suggest that the clinical efficacy of antiplatelet drugs is likely related to their ability to interfere with thrombus formation. " 01/01/1992 - "Clinical trials have shown that antiplatelet agents are effective in the prevention of thrombosis in arterial diseases and increase bleeding time. " 08/01/2012 - "The research of compounds that antagonize P2Y(1) and, in particular, P2Y(12) receptors is of great interest in the aim to obtain platelet aggregation inhibitors that are effective in the prevention and treatment of arterial thrombosis. "
3.	Myocardial Infarction 01/01/1989 - "Meta-analysis of several previous clinical trials, most of which were inconclusive, has recently ascertained the benefit of antiplatelet drugs in secondary prevention of myocardial infarction. " 03/01/1982 - "Clinical trials of antiplatelet agents in the secondary prevention of myocardial infarction and transient ischaemic attacks have so far been inconclusive. " 01/01/2015 - "Two months earlier, she had suffered a non-ST elevation myocardial infarction treated with percutaneous coronary intervention (PCI) and stenting, and she had been prescribed the classical post-PCI therapy (β-blockers, statins and antiplatelet agents). " 08/01/2014 - "Effect of renin-angiotensin system inhibitors on long-term survival in patients treated with beta blockers and antiplatelet agents after acute myocardial infarction (from the MONICA/KORA Myocardial Infarction Registry)." 04/01/2014 - "Introduction of new oral antiplatelet drugs in myocardial infarction hospital network: initial experience."
4.	Hemorrhage 10/01/2011 - "With the advent of newer, more potent antiplatelet agents and their associated increased bleeding risks, it will become imperative in the future to select the most appropriate, safe and effective drug." 11/01/2012 - "Currently available antiplatelet agents have shown improved short- and long-term clinical outcomes but are associated with increased bleeding risk, and the rates of recurrent ischemic events still remain high. " 01/01/2010 - "Using logistic regression analysis, a significant reduction of mortality was estimated for the use of antiplatelet drugs in various subgroups of patients with normal or high bleeding risk (odds ratios, 0.04-0.34). " 03/01/2008 - "Combination strategies for platelet inhibition and platelet inhibition with anticoagulation are beneficial in properly selected patients; however, combining platelet inhibitors with each other and with anticoagulation generally increases bleeding risk. " 12/10/2015 - "Recent post hoc analyses of several clinical trials with P2Y12 antagonists showed the need for new molecules being fully efficacious as antiplatelet agents and having a reduced propensity to cause major bleeding. "
5.	Cardiovascular Diseases (Cardiovascular Disease) 10/01/2011 - "Several novel antiplatelet agents have been found to be effective in reducing the morbidity and mortality associated with cardiovascular disease. " 09/25/1990 - "The protective effects of platelet inhibitors in primary and particularly in secondary prevention of cardiovascular diseases have been documented in numerous studies. " 01/01/2006 - "This article reviews the centrality of the platelet in atherothrombosis and briefly looks at the efficacy of antiplatelet agents in preventing and treating cardiovascular disease." 01/01/2015 - "In this report, we review available data from clinical trials of antiplatelet drugs administered for primary and secondary prevention, focusing on the underenrollment of female subjects in interventional randomized studies and weak community awareness of the impact of cardiovascular disease on life expectancy in women. " 09/01/2010 - "The balance of benefits and risks of antiplatelet drugs in cardiovascular disease has been evaluated in large-scale randomised trials, however the absolute benefit for an individual patient and a specific platelet-active drug needs further evaluation. "

Related Drugs and Biologics

1.	Aspirin (Acetylsalicylic Acid)
2.	Anticoagulants
3.	clopidogrel (Plavix)
4.	Dipyridamole (Persantine)
5.	Warfarin (Coumadin)
6.	Ticlopidine (Ticlid)
7.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
8.	Glycoproteins (Glycoprotein)
9.	cilostazol (Pletal)
10.	Heparin (Liquaemin)

Related Therapies and Procedures

1.	Stents
2.	Transplants (Transplant)
3.	Carotid Endarterectomy
4.	Angioplasty (Angioplasty, Transluminal)
5.	Plasmapheresis